Skip to main content
Erschienen in: World Journal of Urology 9/2023

Open Access 15.07.2023 | Original Article

Prospective evaluation of functional outcomes in 395 patients with an ileal neobladder 1 year after radical cystectomy

verfasst von: Henning Bahlburg, Fabian Schuster, Karl Heinrich Tully, Marius Cristian Butea-Bocu, Moritz Reike, Florian Roghmann, Joachim Noldus, Guido Mueller

Erschienen in: World Journal of Urology | Ausgabe 9/2023

Abstract

Purpose

This study aims to report on functional outcomes in a large cohort of patients who underwent inpatient rehabilitation (IR) in a highly specialized, high-volume German urologic rehabilitation center after radical cystectomy (RC) and creation of an ileal neobladder (INB).

Methods

Data for 842 patients, who underwent three weeks of IR after RC and urinary diversion between April 2018 and December 2019 were prospectively collected. INB patients were surveyed on continence and sexual function. Data were collected at 4 weeks (T1), 6 months (T2), and 12 months (T3) after RC. Multivariate logistic regressions were performed to identify predictors of better functional outcomes.

Results

INB was chosen as urinary diversion in 395 patients (357 male, 38 female). Social continence (maximum of one safety pad/24 h) was reported by 78.3% of men and 64.0% of women at T3. Severe incontinence was reported by 27.3% of men and 44.0% of women. Male sex was identified as an independent predictor for the use of no pads at T3 (OR 4.110; 95% CI 1.153–14.655; p = 0.029). Nerve-sparing surgery was identified as an independent predictor both for the use of only a safety pad (OR 1.918; 95% CI 1.031–3.569; p = 0.040) and good erectile function at T3 (OR 4.377; 95% CI 1.582–12.110; p = 0.004).

Conclusion

Urologists should aspire for nerve-sparing surgery. When advising patients before RC, functional outcomes (continence, sexual function) should be given special attention. Women should be counseled on potentially prolonged urinary incontinence.
Hinweise
Henning Bahlburg and Fabian Schuster have contributed equally to this work.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

It is known that in patients with an ileal neobladder (INB), urinary continence is an independent prognostic factor for a high quality of life (QoL) post-surgery, while incontinence may lead to diminished body image [1, 2]. In current literature, continence rates after creation of an INB vary from 49 to 96% during the daytime and 35–95% at night. Continence rates increase over time and are higher in men than in women [2, 3]. An impaired emotional and cognitive function in patients with an INB due to urinary incontinence has been reported [2]. A low-pressure reservoir and an intact external urethral sphincter are important factors for postoperative continence [4]. Continence in general, but especially during daytime, is improved by nerve-sparing surgery [57]. Several factors such as water diffusion from the intestinal wall into the reservoir, a decreased sphincter tonus, and peaks in intraluminal pressure by increased peristaltic movements have been discussed as influencing nocturnal incontinence [810]. As function of the external urethral sphincter deteriorates with age, patients younger than 65 reach higher continence rates [1113]. Accordingly, the study by Erdogan et al. identified increasing age, diabetes, and a body mass index ≥ 30 kg/m2 as independent negative predictors of urinary continence in the early postoperative period [7].
When performing radical cystectomy (RC), nerve-sparing surgery should be aspired for when feasible as stated in the current guideline by the European Association of Urology [14]. In addition to urinary incontinence, erectile dysfunction (ED) following surgery may also negatively influence quality of life [5, 15, 16].
So that patients can reach the important goal of reintegration into daily life, German social laws entitle cancer patients to an average of 3 weeks of inpatient rehabilitation (IR). The guideline of the German Society of Urology recommends that all patients be offered several weeks of IR after RC for bladder cancer to minimize functional disorders [17]. It is assumed that in Germany almost all patients participate in IR as recommended. The design of our study allows us to report on the functional outcomes of a large number of INB patients in a recent period.

Methods

This prospective study was based on clinical data of patients with urothelial carcinoma of the bladder who had received RC and INB creation in various hospitals across Germany and who were treated in a specialized center for urological rehabilitation (Kliniken Hartenstein, Bad Wildungen, Germany) between April 2018 and December 2019. The study protocol was approved by an institutional research committee (research authorization number FF30/2017). At the beginning of IR (T1) and at both 6 (T2) and 12 months (T3) after surgery, continence and erectile function were measured by validated questionnaires.

Inpatient rehabilitation (IR)

During IR, patients were treated by specialized physiotherapists regarding urinary continence. The multimodal continence therapy includes osteopathic physiotherapy, external urethral sphincter exercises, and educational measures on neobladder management and care (e.g. micturition diary with instruction to empty the neobladder initially every 2–3 h during the day as well as at night; careful increase of neobladder volume to achieve sensitivity concerning neobladder volume; and prevention of residual urine volume with special mechanisms for emptying the neobladder). For patients without improvement in daytime continence within two weeks of therapy, video-assisted biofeedback-sphincter training via transurethral endoscopy can be performed [7].

International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)

The ICIQ-SF is a validated patient-reported assessment and examines the frequency and quantity of involuntary loss of urine and its influence on QoL [18]. The questionnaire consists of three scored items, scored on a Likert-scale between 0 and 5. Zero points are equivalent to no impairment while a score of 5 points is equivalent to a very high impairment. The total sum of all three scored items allows for classifying the patients’ incontinence into three groups. A sum between 1 and 5 points is defined as mild, a score between 6 and 10 points as moderate, and a score ≥ 11 as severe incontinence [19]. Additionally, the number of pads used daily is examined. Social continence was defined as the use of a maximum of one safety pad per 24 h.

International Index of Erectile Function (IIEF-5)

The IIEF-5 is a validated, patient-reported tool to measure erectile function and was developed based on the International Index of Erectile Function, containing 15 items [20]. Its five items concern erectile function, sexual desire, orgasm ability, and sexual satisfaction. Each question is scored on a Likert-scale of 1–5. 1 point equals a high impairment, and 5 points equals no impairment. The erectile function can then be classified according to the sum of all scores. A score of 5–7 points signals severe, a score between 8 and 11 moderate, a score of 12–16 weak to moderate, a score of 17–21 weak, and a score of 22–25 points no erectile dysfunction (ED).

Erection Hardness Score (EHS)

The EHS offers another easy tool to measure erectile function, in which the erection is scored on a 5-point Likert-scale (0–4) [21]. The result can be interpreted as follows. Zero points: the penis does not enlarge when the patient is sexually aroused. One point: the penis enlarges but does not get hard. Two points: the penis is hard but not sufficiently so for penetration. Three points: the penis is hard enough for penetration but not totally hard. Four points: the penis is hard and rigid.

Statistical analyses

The Wilcoxon test and a Chi-squared test (McNemar) were used to assess the level of significance regarding changes during follow-up in quantitative variables and proportions. Multivariate logistic regression was performed to identify predictors for “safety pad” and “no pad” 1 year after surgery. Significance was considered at p < 0.05. Analyses were performed using SPSS, version 29 (IBM, Chicago, IL, USA).

Results

A total of 842 patients after RC from 135 different hospitals in Germany underwent IR in the aforementioned timeframe, of which 395 patients (46.9%) received an INB. Their characteristics are summarized in Table 1. The median age was 64 years (IQR 58–69). The majority of patients were male (90.4%). IR started at a median of 28 days (IQR 23–35) and ended with a median of 54 days (IQR 48–62) after surgery. The response rates for the follow-up survey were 83.0% (n = 328) at T2 and 71.6% (n = 283) at T3.
Table 1
Characteristics of 395 patients after radical cystectomy and creation of an ileal neobladder
Variable
Value
Patients, n (%)
395 (100)
Age (years), Median (IQR)
64 (58–69)
 ≤ 59 years, n (%)
123 (31.1)
 60–69 years, n (%)
182 (46.1)
 ≥ 70 years, n (%)
90 (22.8)
Sex, n (%)
 
 Male
357 (90.4)
 Female
38 (9.6)
BMI (kg/m2), Median (IQR)
25 (23–27)
 < 30, n (%)
353 (89.4)
 ≥ 30, n (%)
42 (11.6)
Cardiovascular disease, n (%)
221 (55.9)
Diabetes, n (%)
42 (10.6)
Neoadjuvant chemotherapy, n (%)
46 (11.6)
Method of surgery, n (%)
 
 Open cystectomy
348 (88.1)
 Robot-assisted cystectomy
47 (11.9)
Tumor stage, n (%)
 
 ≤ pT2
300 (75.9)
 ≥ pT3
95 (24.1)
Lymph node positive, n (%)a
45 (11.8)
No. of lymph nodes removed, Median (IQR)
17 (12–24)
IQR interquartile range, BMI body mass index
aData available for 382 patients

Continence

Data on continence outcomes for men enrolled in this study can be found in Table 2a.
Table 2
Continence after radical cystectomy and creation of an ileal neobladder
 
T1
T2
T3
(a) Male patients
   
 ICIQ Score, Median (IQR)
15 (12–18)
7 (4–11)*
7 (4–11)
 Continence (score 0), n (%)
5 (1.5)
34 (11.5)*
36 (14.2)
 Mild incontinence (score 1–5), n (%)
14 (4.1)
87 (29.5)*
72 (28.5)
 Moderate incontinence (score 6–10), n (%)
46 (13.4)
91 (30.8)*
76 (30.0)
 Severe incontinence (score ≥ 11), n (%)
279 (81.1)
83 (28.1)*
69 (27.3)
 Pads at day, Median (IQR)
4 (2–6)
1 (1–2)*
1 (1–2)
 Pads at night, Median (IQR)
3 (2–4)
1 (1–2)*
1 (1–2)*
 “Safety pad”, n (%)
68 (19.0)
135 (45.8)*
109 (42.9)
 “No pad”, n (%)
5 (1.5)
93 (31.5)*
90 (35.4)
(b) Female patients
   
 ICIQ Score, Median (IQR)
10 (10–18)
13 (5–19)
8 (3–13)
 Continence (score 0), n (%)
4 (10.5)
3 (10.3)
5 (20)
 Mild incontinence (score 1–5), n (%)
3 (7.9)
5 (17.2)
6 (24.0)
 Moderate incontinence (score 6–10), n (%)
3 (7.9)
5 (17.2)
3 (12.0)
 Severe incontinence (score ≥ 11), n (%)
28 (73.7)
16 (55.2)*
11 (44.0)
 Pads at day, Median (IQR)
5 (4–8)
4 (2–6)*
2.5 (1–5)
 Pads at night, Median (IQR)
3 (2–4)
2 (1–4)*
1 (1–2.5)*
 “Safety pad”, n (%)
6 (15.8)
9 (31.0)
13 (52.0)
 “No pad”, n (%)
2 (5.3)
3 (10.3)
3 (12.0)
Significant results are shown in bold
(Wilcoxon-test or Chi squared test (McNemar) as appropriate)
ICIQ International Consultation on Incontinence Questionnaire (short form), T1 4 weeks after surgery (data available for 344 men and 38 women), T2 6 months after surgery (data available for 295 men and 29 women), T3 12 months after surgery (data available for 253 men and 25 women)
*p < 0.05 for the difference to the last time of evaluation
At T1, men reached a median score of 15 (IQR 12–18) in the ICIQ-SF. Continence improved significantly to a median score of 7 (IQR 4–11, p < 0.05) 6 months post-surgery. 12 months post-surgery, a median score of 7 (IQR 6–10) was reported, signaling moderate incontinence. At T1, 1.5% (n = 5) reported complete continence. A significant increase in men with complete continence (ICIQ-score = 0) was seen at T2 (11.5%). Light incontinence (ICIQ = 1–5) was reported by 29.5% of men. Accordingly, the rate of men with severe incontinence (ICIQ =  ≥ 11) decreased from 81.1% at T1 to 28.1% at T2. During further follow-up, no statistically significant improvements were detected. 14.2% of men were continent 12 months post-surgery, while 28.5% reported light incontinence. Thirty percent reported moderate incontinence, and 27.3% had severe incontinence. At T1, men used a median of 4 pads during the day (IQR 2–6) and 3 pads (IQR 2–4) during the night. Use of pads decreased significantly to 1 pad during the day and 1 pad during the night at T2 (IQR 1–2; p < 0.05). The number of pads used remained the same at T3. The percentage of men using a safety pad increased significantly to 45.8% at T2 (p < 0.05). At T2, a significantly higher portion of men did not need any safety pad (31.5%, p < 0.05). Social continence was reported by 78.3% of men at T3.
Data on continence rates in female participants can be found in Table 2b. Female patients reached a median ICIQ score of 8 points (IQR 3–13) 12 months post-surgery. Twenty percent of women reported complete continence at T3. However, 44.0% were still limited by severe incontinence (ICIQ ≥ 11) at this point. Median use of pads decreased to 2.5 (IQR 1–5) during the day and 1 pad (IQR 1–2.5) during the night. At T3, 52.0% of women used only a safety pad, while 12.0% used no pad at all. Thus, social continence was reached by 64.0% of women included in this study.
Multivariate regression analysis (Table 3) identified nerve-sparing surgery as an independent positive predictor for the use of a safety pad only at T3 (OR 1.918; 95% CI 1.031–3.569; p = 0.040). Male sex was identified as an independent positive predictor for the use of no pads at T3 (OR 4.110; 95% CI 1.153–14.655; p = 0.029).
Table 3
Multivariate regression analysis to identify independent predictors for “safety pad” and “no pad” 1 year after radical cystectomy and creation of an ileal neobladder
Variable
“Safety pad”
“No pad”
OR (95% CI)
p
OR (95% CI)
p
Age ≤ 59 years vs. ≥ 60 years
0.967 (0.515–1.816)
0.917
1.359 (0.752–2.454)
0.310
Male vs. female
0.719 (0.301–1.717)
0.458
4.110 (1.153–14.655)
0.029
BMI ≥ 30 kg/m2 (yes vs. no)
0.601 (0.235–1.538)
0.288
1.194 (0.481–2.962)
0.703
Diabetes (yes vs. no)
0.609 (0.222–1.669)
0.335
1.575 (0.624–3.978)
0.336
Cardiovascular disease (yes vs. no)
1.709 (0.965–3.026)
0.066
0.605 (0.343–1.065)
0.081
Open vs. Robot-assisted surgery
1.045 (0.479–2.284)
0.911
1.845 (0.782–4.353)
0.162
Nerve sparing (yes vs. no)
1.918 (1.031–3.569)
0.040
0.967 (0.544–1.719)
0.909
Significant results (p < 0.05) are shown in bold
OR odds ratio, CI confidence interval, BMI body mass index

Erectile function

Information on erectile function pre-surgery was available for 99.2% of men. Before surgery, 77.4% of men reported an erectile function sufficient for sexual intercourse (EHS ≥ 3). Data on erectile function are shown in Table 4.
Table 4
Erectile function after radical cystectomy and creation of an ileal neobladder evaluated by IIEF-5 and EHS
All patients
T1
T2
T3
Patients with EHS ≥ 3 before surgery and NS
T1
T2
T3
IIEF-5 score, available for
n = 271
n = 254
n = 217
IIEF-5 score, available for
n = 82
n = 94
n = 83
Median (IQR)
6 (5–7)
5 (5–7)
5 (5–8)
Median (IQR)
7 (6–9)
6 (5–10)
7 (5–13)
 22–25, n (%)
12 (4.4)
7 (2.8)
7 (3.2)
22–25, n (%)
9 (11.0)
6 (6.4)
6 (7.2)
 17–21, n (%)
13 (4.8)
8 (3.1)
11 (5.1)
17–21, n (%)
4 (4.9)
5 (5.3)
7 (8.4)
 12–16, n (%)
10 (3.7)
15 (5.9)
17 (7.8)
12–16, n (%)
2 (2.4)
10 (10.6)
14 (16.9)*
 8–11, n (%)
29 (10.7)
33 (13.0)
26 (12.0)
8–11, n (%)
11 (13.4)
15 (16.0)
11 (13.3)
 5–7, n (%)
207 (76.4)
191 (75.2)
156 (71.9)
5–7, n (%)
56 (68.3)
58 (61.7)
45 (54.2)
EHS, available for
n = 272
n = 270
n = 220
EHS, available for
n = 84
n = 99
n = 83
EHS ≥ 3, n (%)
15 (5.5)
25 (9.3)
24 (10.9)
EHS ≥ 3, n (%)
10 (11.9)
17 (17.2)
16 (19.3)
Significant results are shown in bold
IIEF-5 International Index of Erectile Function (5-item version), EHS erection hardness score (≥ 3: erectile function sufficient for sexual intercourse), NS nerve sparing, T1 4 weeks after surgery, T2 6 months after surgery, T3 12 months after surgery
*p = 0.002 for T1 vs. T3 calculated by the Chi-squared test (McNemar)

IIEF-5

Results showed that more than 70% of men were suffering from severe ED during follow-up. Only 8.3% reported no or only a weak ED (IIEF-score ≥ 17).
Before surgery, 116 men (median age 60 years, IQR 55–66) had a sufficient erection (EHS ≥ 3) and underwent nerve-sparing surgery. Weak to moderate ED was reported by 2.4% of these men at T1. However, this portion increased significantly to 16.9% at T3. At T3, only 15.6% reported no or only a weak ED, while 54.2% suffered from complete ED. Multivariate regression analysis (Table 5) identified nerve-sparing surgery as the only independent predictor for erectile function 1 year after RC (OR 4.377; 95% CI 1.582–12.110; p = 0.004). A trend towards significance was observed when comparing robot-assisted and open RC (p = 0.051).
Table 5
Multivariate regression analysis to identify independent predictors for an erectile function fit for sexual intercourse (EHS ≥ 3) 1 year after RC
Variable
OR (95% CI)
p
Age ≤ 59 years vs. ≥ 60 years
1.179 (0.448–3.105)
0.739
BMI ≥ 30 kg/m2 (yes vs. no)
3.718 (0.818–16.892)
0.089
Diabetes (yes vs. no)
0.961 (0.188–4.924)
0.962
Cardiovascular disease (yes vs. no)
1.321 (0.484–3.606)
0.587
Robot-assisted vs. open surgery
2.835 (0.994–8.087)
0.051
Nerve sparing (yes vs. no)
4.377 (1.582–12.110)
0.004
Significant results (p < 0.05) are shown in bold
EHS erection hardness score, OR odds ratio, CI confidence interval, BMI body mass index

EHS

4 weeks after surgery, 5.5% of men reported an erectile function sufficient for sexual intercourse (EHS ≥ 3). During follow-up, this cohort steadily grew. At T3, 10.9% reported an EHS ≥ 3. In men who had a pre-surgery EHS ≥ 3 and underwent nerve-sparing surgery, 19.3% reported an EHS ≥ 3 at T3.

Comparison of functional outcomes in relation to nerve-sparing surgery (Table 6)

Table 6
Functional outcomes in men 1 year after surgery related to  nerve-sparing surgery
Variable
NS
nNS
pa
Age (years), median (IQR)
60.5 (55.5–67.0)
65.0 (60.0–70.0)
 < 0.001
ICIQ-Score
6.5 (4.0–11.0)
7.0 (4.0–11.0)
0.291
“Social continence” (≤ 1 pad in 24 h)
57 (58.2)
111 (69.8)
0.057
“No pad”, n (%)
36 (36.7)
54 (34.8)
0.759
“Safety pad”, n (%)
21 (21.4)
57 (35.8)
0.015
EHS ≥ 3, n (%)
17 (18.5)
7 (5.4)
0.002
Significant results (p < 0.05) are shown in bold
Data concerning “social continence” available for 159 men with nNS and 98 men with NS
Data concerning “no pad” available for 155 men with nNS and 98 men with NS
Data concerning “safety pad” available for 159 men with nNS and 98 men with NS
Data concerning EHS available for 130 men with nNS and 92 men with NS
NS nerve-sparing surgery, nNS non-nerve-sparing surgery, EHS erection hardness score (≥ 3: erectile function fit for sexual intercourse)
aMann–Whitney U test or Chi-squared test (Pearson) as appropriate
When comparing functional results of men undergoing nerve-sparing surgery to those of men without nerve-sparing surgery, several significant differences were detected. Firstly, men undergoing nerve-sparing surgery were significantly younger (median age 60.5 years (IQR 55.5–67) vs. 65 years (IQR 60–70); p < 0.001). Furthermore, after nerve-sparing surgery, patients were significantly less likely to need a safety pad (21.4% vs 37%; p = 0.008) and more likely to report an erectile function sufficient for sexual intercourse (EHS ≥ 3; 18.5% vs 5.4%; p = 0.002).

Discussion

After RC and creation of an INB, urinary continence may be the most important factor for a high QoL [2]. According to our data, social continence (0–1 pad per 24 h) was reached by 78.3% of men and 64.0% of women 12 months after creation of an INB. The difference in continence rates between genders is backed up by data from the literature [2, 3]. Multivariate regression analysis identified nerve-sparing surgery as an independent predictor for the use of one safety pad 12 months post-surgery, while male sex was identified as an independent predictor for the use of no pads. Clifford et al. reported on 188 patients, of which 49% reached social continence 18–36 months post-surgery [12]. Novara et al. reported on 113 patients, who had surgery between 2002 and 2006 and were evaluated by the ICIQ. In this cohort, 18% reached complete continence, while 68% did not use any pads [22]. Ahmadi et al. examined 179 men with an ileum neobladder 12 months post-surgery. In this cohort, 15% did not use any pads [23]. The larger cohort in our study and improved surgical technique (laparoscopic, robot-assisted) with high-definition, 3D vision, may explain a higher rate of socially continent patients than in the aforementioned studies. Furthermore, structured urologic rehabilitation in a specialized center may also influence functional outcomes after RC.
Data on sexual function after radical cystectomy vary enormously. Schoenberg et al. reported an improved sexual function in younger men over time with potency rates of up to 50% 10 years after surgery [24]. According to current literature, potency rates up to 65% can be reached in carefully selected collectives [6]. However, other studies showed potency rates of 10–20% only [22, 25]. Even if nerve-sparing surgery is not possible, up to 35% of men may still have sufficient erectile function [26]. Nonetheless, according to an American study, only 15% of men receive sufficient treatment for their ED [27].
Before surgery, 77.4% of men in the present cohort were potent (EHS ≥ 3). However, only 19.3% of men who were potent before surgery and underwent nerve-sparing surgery had sufficient erectile function 12 months post-surgery. At the same time, only 8.3% of all patients suffered from no or weak ED (IIEF-5 score ≥ 17). On the contrary, about 70% of all men reported a severe ED (IIEF-5 score 5–7) during follow-up. As identified by multivariate regression analysis, nerve-sparing surgery is the only independent predictor for good erectile function 12 months after surgery. After nerve-sparing surgery, a significantly greater portion of men reported good erectile function, and they were less likely to use a safety pad. About 50% of men aged 65–75 are still sexually active [28]. There is a desire among cancer patients to gain information about the influence of cancer and its respective treatment on their sexuality. However, patients often refrain from talking about their sexual desires and medical professionals seldom raise this issue [29]. If applied, a structured penile rehabilitation including andrological examinations, intake of phosphodiesterase inhibitors, use of vacuum pumps, and intracavernous injections with Alprostadil may lead to improved sexual function 12 months after surgery [30].
In this study, patients from various urologic departments with different levels of experience from all over Germany were included. An improved functional outcome may be achieved when surgery is performed in specialized centers. However, this was not evaluated in this study. Information about nerve-sparing surgery was taken from discharge papers and surgical reports and could thus not be independently validated. The actual percentage of patients who had nerve-sparing surgery may be lower than reported, leading to worse results concerning erectile function.
Nonetheless, by using validated questionnaires, this study offers a unique insight into continence and potency rates 4 weeks, 6 months, and 12 months after RC and creation of an INB. Currently, about 1600 patients undergo RC with creation of an INB in Germany annually. Almost one quarter of these patients is included in this study. Thus, our study reports real-world data acquired in a recent period. Even if nerve-sparing surgery is performed, potency rates are low. Continence rates improve over time. However, more than 20% of male patients and more than 35% of female patients with an INB still report relevant urinary incontinence 12 months after surgery.

Conclusion

When advising patients concerning urinary diversion, functional outcomes concerning continence and sexual function should receive special attention. In particular, female patients should be informed about potentially prolonged incontinence.

Acknowledgements

We would like to thank Steve Martindale for proof-reading the initial manuscript. Further gratitude is extended to Joshua Scurll, PhD, for proof-reading the revised manuscript.

Declarations

Conflict of interest

All authors declare no conflict of interest, contributed substantially to this manuscript, and all gave explicit consent to submission.

Ethical approval

The study protocol was approved by an institutional research committee (research authorization number FF30/2017).
Patients provided written informed consent for participation in this study.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Gynäkologie

Kombi-Abonnement

Mit e.Med Gynäkologie erhalten Sie Zugang zu CME-Fortbildungen der beiden Fachgebiete, den Premium-Inhalten der Fachzeitschriften, inklusive einer gedruckten gynäkologischen oder urologischen Zeitschrift Ihrer Wahl.

e.Med Urologie

Kombi-Abonnement

Mit e.Med Urologie erhalten Sie Zugang zu den urologischen CME-Fortbildungen und Premium-Inhalten der urologischen Fachzeitschriften.

Literatur
1.
Zurück zum Zitat Kretschmer A, Grimm T, Buchner A, Stief CG, Karl A (2016) Prognostic features for quality of life after radical cystectomy and orthotopic neobladder. Int Braz J Urol 42:1109–1120CrossRefPubMedPubMedCentral Kretschmer A, Grimm T, Buchner A, Stief CG, Karl A (2016) Prognostic features for quality of life after radical cystectomy and orthotopic neobladder. Int Braz J Urol 42:1109–1120CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Grimm T, Grimm J, Buchner A, Schulz G, Jokisch F, Stief CG et al (2019) Health-related quality of life after radical cystectomy and ileal orthotopic neobladder: effect of detailed continence outcomes. World J Urol 37:2385–2392CrossRefPubMed Grimm T, Grimm J, Buchner A, Schulz G, Jokisch F, Stief CG et al (2019) Health-related quality of life after radical cystectomy and ileal orthotopic neobladder: effect of detailed continence outcomes. World J Urol 37:2385–2392CrossRefPubMed
3.
Zurück zum Zitat Todenhofer T, Stenzl A, Schwentner C (2013) Optimal use and outcomes of orthotopic neobladder reconstruction in men and women. Curr Opin Urol 23:479–486CrossRefPubMed Todenhofer T, Stenzl A, Schwentner C (2013) Optimal use and outcomes of orthotopic neobladder reconstruction in men and women. Curr Opin Urol 23:479–486CrossRefPubMed
4.
Zurück zum Zitat Kakizaki H, Shibata T, Ameda K, Shinno Y, Nonomura K, Koyanagi T (1995) Continence mechanism of the orthotopic neobladder: urodynamic analysis of ileocolic neobladder and external urethral sphincter functions. Int J Urol 2:267–272CrossRefPubMed Kakizaki H, Shibata T, Ameda K, Shinno Y, Nonomura K, Koyanagi T (1995) Continence mechanism of the orthotopic neobladder: urodynamic analysis of ileocolic neobladder and external urethral sphincter functions. Int J Urol 2:267–272CrossRefPubMed
5.
Zurück zum Zitat Furrer MA, Studer UE, Gross T, Burkhard FC, Thalmann GN, Nguyen DP (2018) Nerve-sparing radical cystectomy has a beneficial impact on urinary continence after orthotopic bladder substitution, which becomes even more apparent over time. BJU Int 121:935–944CrossRefPubMed Furrer MA, Studer UE, Gross T, Burkhard FC, Thalmann GN, Nguyen DP (2018) Nerve-sparing radical cystectomy has a beneficial impact on urinary continence after orthotopic bladder substitution, which becomes even more apparent over time. BJU Int 121:935–944CrossRefPubMed
6.
Zurück zum Zitat Colombo R, Pellucchi F, Moschini M, Gallina A, Bertini R, Salonia A et al (2015) Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients. World J Urol 33:1389–1395CrossRefPubMed Colombo R, Pellucchi F, Moschini M, Gallina A, Bertini R, Salonia A et al (2015) Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients. World J Urol 33:1389–1395CrossRefPubMed
7.
Zurück zum Zitat Erdogan B, Berg S, Noldus J, Muller G (2021) Early continence after ileal neobladder: objective data from inpatient rehabilitation. World J Urol 39:2531–2536CrossRefPubMed Erdogan B, Berg S, Noldus J, Muller G (2021) Early continence after ileal neobladder: objective data from inpatient rehabilitation. World J Urol 39:2531–2536CrossRefPubMed
8.
Zurück zum Zitat Mills RD, Studer UE (1999) Metabolic consequences of continent urinary diversion. J Urol 161:1057–1066CrossRefPubMed Mills RD, Studer UE (1999) Metabolic consequences of continent urinary diversion. J Urol 161:1057–1066CrossRefPubMed
9.
Zurück zum Zitat El-Bahnasawy MS, Gomha MA, Shaaban AA (2006) Urethral pressure profile following orthotopic neobladder: differences between nerve sparing and standard radical cystectomy techniques. J Urol 175:1759–1763CrossRefPubMed El-Bahnasawy MS, Gomha MA, Shaaban AA (2006) Urethral pressure profile following orthotopic neobladder: differences between nerve sparing and standard radical cystectomy techniques. J Urol 175:1759–1763CrossRefPubMed
10.
Zurück zum Zitat El Bahnasawy MS, Osman Y, Gomha MA, Shaaban AA, Ashamallah A, Ghoneim MA (2000) Nocturnal enuresis in men with an orthotopic ileal reservoir: urodynamic evaluation. J Urol 164:10–13CrossRefPubMed El Bahnasawy MS, Osman Y, Gomha MA, Shaaban AA, Ashamallah A, Ghoneim MA (2000) Nocturnal enuresis in men with an orthotopic ileal reservoir: urodynamic evaluation. J Urol 164:10–13CrossRefPubMed
11.
Zurück zum Zitat Kessler TM, Burkhard FC, Perimenis P, Danuser H, Thalmann GN, Hochreiter WW et al (2004) Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J Urol 172:1323–1327CrossRefPubMed Kessler TM, Burkhard FC, Perimenis P, Danuser H, Thalmann GN, Hochreiter WW et al (2004) Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J Urol 172:1323–1327CrossRefPubMed
12.
Zurück zum Zitat Clifford TG, Shah SH, Bazargani ST, Miranda G, Cai J, Wayne K et al (2016) Prospective evaluation of continence following radical cystectomy and orthotopic urinary diversion using a validated questionnaire. J Urol 196:1685–1691CrossRefPubMed Clifford TG, Shah SH, Bazargani ST, Miranda G, Cai J, Wayne K et al (2016) Prospective evaluation of continence following radical cystectomy and orthotopic urinary diversion using a validated questionnaire. J Urol 196:1685–1691CrossRefPubMed
13.
Zurück zum Zitat Hammerer P, Michl U, Meyer-Moldenhauer WH, Huland H (1996) Urethral closure pressure changes with age in men. J Urol 156:1741–1743CrossRefPubMed Hammerer P, Michl U, Meyer-Moldenhauer WH, Huland H (1996) Urethral closure pressure changes with age in men. J Urol 156:1741–1743CrossRefPubMed
14.
Zurück zum Zitat Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G et al (2021) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79:82–104CrossRefPubMed Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G et al (2021) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79:82–104CrossRefPubMed
15.
Zurück zum Zitat Lu Y, Fan S, Cui J, Yang Y, Song Y, Kang J et al (2020) The decline in sexual function, psychological disorders (anxiety and depression) and life satisfaction in older men: a cross-sectional study in a hospital-based population. Andrologia 52:e13559CrossRefPubMed Lu Y, Fan S, Cui J, Yang Y, Song Y, Kang J et al (2020) The decline in sexual function, psychological disorders (anxiety and depression) and life satisfaction in older men: a cross-sectional study in a hospital-based population. Andrologia 52:e13559CrossRefPubMed
16.
Zurück zum Zitat Vogt K, Netsch C, Becker B, Oye S, Gross AJ, Rosenbaum CM (2021) Perioperative and pathological outcome of nerve-sparing radical cystectomy with ileal neobladder. Front Surg 8:652958CrossRefPubMedPubMedCentral Vogt K, Netsch C, Becker B, Oye S, Gross AJ, Rosenbaum CM (2021) Perioperative and pathological outcome of nerve-sparing radical cystectomy with ileal neobladder. Front Surg 8:652958CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P (2004) ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 23:322–330CrossRefPubMed Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P (2004) ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 23:322–330CrossRefPubMed
19.
Zurück zum Zitat Klovning A, Avery K, Sandvik H, Hunskaar S (2009) Comparison of two questionnaires for assessing the severity of urinary incontinence: the ICIQ-UI SF versus the incontinence severity index. Neurourol Urodyn 28:411–415CrossRefPubMed Klovning A, Avery K, Sandvik H, Hunskaar S (2009) Comparison of two questionnaires for assessing the severity of urinary incontinence: the ICIQ-UI SF versus the incontinence severity index. Neurourol Urodyn 28:411–415CrossRefPubMed
20.
Zurück zum Zitat Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319–326CrossRefPubMed Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319–326CrossRefPubMed
21.
Zurück zum Zitat Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K (2007) Validation of the erection hardness score. J Sex Med 4:1626–1634CrossRefPubMed Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K (2007) Validation of the erection hardness score. J Sex Med 4:1626–1634CrossRefPubMed
22.
Zurück zum Zitat Novara G, Ficarra V, Minja A, De Marco V, Artibani W (2010) Functional results following vescica ileale Padovana (VIP) neobladder: midterm follow-up analysis with validated questionnaires. Eur Urol 57:1045–1051CrossRefPubMed Novara G, Ficarra V, Minja A, De Marco V, Artibani W (2010) Functional results following vescica ileale Padovana (VIP) neobladder: midterm follow-up analysis with validated questionnaires. Eur Urol 57:1045–1051CrossRefPubMed
23.
Zurück zum Zitat Ahmadi H, Skinner EC, Simma-Chiang V, Miranda G, Cai J, Penson DF et al (2013) Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. J Urol 189:1782–1788CrossRefPubMed Ahmadi H, Skinner EC, Simma-Chiang V, Miranda G, Cai J, Penson DF et al (2013) Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. J Urol 189:1782–1788CrossRefPubMed
24.
Zurück zum Zitat Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL, Brendler CB (1996) Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup. J Urol 155:490–494CrossRefPubMed Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL, Brendler CB (1996) Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup. J Urol 155:490–494CrossRefPubMed
25.
Zurück zum Zitat Takenaka A, Hara I, Soga H, Sakai I, Terakawa T, Muramaki M et al (2011) Assessment of long-term quality of life in patients with orthotopic neobladder followed for more than 5 years. Int Urol Nephrol 43:749–754CrossRefPubMed Takenaka A, Hara I, Soga H, Sakai I, Terakawa T, Muramaki M et al (2011) Assessment of long-term quality of life in patients with orthotopic neobladder followed for more than 5 years. Int Urol Nephrol 43:749–754CrossRefPubMed
26.
Zurück zum Zitat Asgari MA, Safarinejad MR, Shakhssalim N, Soleimani M, Shahabi A, Amini E (2013) Sexual function after non-nerve-sparing radical cystoprostatectomy: a comparison between ileal conduit urinary diversion and orthotopic ileal neobladder substitution. Int Braz J Urol 39:474–483CrossRefPubMed Asgari MA, Safarinejad MR, Shakhssalim N, Soleimani M, Shahabi A, Amini E (2013) Sexual function after non-nerve-sparing radical cystoprostatectomy: a comparison between ileal conduit urinary diversion and orthotopic ileal neobladder substitution. Int Braz J Urol 39:474–483CrossRefPubMed
27.
Zurück zum Zitat Chappidi MR, Kates M, Sopko NA, Joice GA, Tosoian JJ, Pierorazio PM et al (2017) Erectile dysfunction treatment following radical cystoprostatectomy: analysis of a nationwide insurance claims database. J Sex Med 14:810–817CrossRefPubMed Chappidi MR, Kates M, Sopko NA, Joice GA, Tosoian JJ, Pierorazio PM et al (2017) Erectile dysfunction treatment following radical cystoprostatectomy: analysis of a nationwide insurance claims database. J Sex Med 14:810–817CrossRefPubMed
28.
Zurück zum Zitat Dekker A, Matthiesen S, Cerwenka S, Otten M, Briken P (2020) Health, sexual activity, and sexual satisfaction. Dtsch Arztebl Int 117:645–652PubMedPubMedCentral Dekker A, Matthiesen S, Cerwenka S, Otten M, Briken P (2020) Health, sexual activity, and sexual satisfaction. Dtsch Arztebl Int 117:645–652PubMedPubMedCentral
29.
Zurück zum Zitat Bober SL, Varela VS (2012) Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol 30:3712–3719CrossRefPubMed Bober SL, Varela VS (2012) Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol 30:3712–3719CrossRefPubMed
30.
Zurück zum Zitat Abozaid M, Tan WS, Khetrapal P, Baker H, Duncan J, Sridhar A et al (2022) Recovery of health-related quality of life in patients undergoing robot-assisted radical cystectomy with intracorporeal diversion. BJU Int 129:72–79CrossRefPubMed Abozaid M, Tan WS, Khetrapal P, Baker H, Duncan J, Sridhar A et al (2022) Recovery of health-related quality of life in patients undergoing robot-assisted radical cystectomy with intracorporeal diversion. BJU Int 129:72–79CrossRefPubMed
Metadaten
Titel
Prospective evaluation of functional outcomes in 395 patients with an ileal neobladder 1 year after radical cystectomy
verfasst von
Henning Bahlburg
Fabian Schuster
Karl Heinrich Tully
Marius Cristian Butea-Bocu
Moritz Reike
Florian Roghmann
Joachim Noldus
Guido Mueller
Publikationsdatum
15.07.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 9/2023
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-023-04520-x

Weitere Artikel der Ausgabe 9/2023

World Journal of Urology 9/2023 Zur Ausgabe

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.